TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Revenue of TransMedics Group, Inc. (TMDX)
Revenue in 2023 (TTM): $241.62 M
According to TransMedics Group, Inc.'s latest financial reports the company's current revenue (TTM) is $241.62 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of TransMedics Group, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $241.62 M | $154.09 M | $-7,603,000 | $-26,671,000 | $-25,028,000 |
| 2022 | $93.46 M | $65.27 M | $-28,961,000 | $-36,165,000 | $-36,231,000 |
| 2021 | $30.26 M | $21.16 M | $-38,488,000 | $-44,179,000 | $-44,215,000 |
| 2020 | $25.64 M | $16.64 M | $-23,154,000 | $-28,716,000 | $-28,748,000 |
| 2019 | $23.6 M | $13.86 M | $-27,932,000 | $-33,507,000 | $-33,547,000 |
| 2018 | $13.02 M | $5.73 M | $-20,226,000 | $-23,715,000 | $-23,756,000 |
| 2017 | $7.69 M | $2.14 M | $-19,089,000 | $-20,791,000 | $-20,823,000 |
| 2016 | $6.21 M | $766 K | $-22,660,000 | $-24,065,000 | $-24,065,000 |